CellCentric
CellCentric - Epigenetics - developing small molecule inhibitors for cancer.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 | round | |
* | $120m | Series C | |
| Total Funding | 000k | ||
| GBP | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | (2186 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | (2184 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | - | - | 1966 % | - | - |
Source: Company filings or news article
Related Content
CellCentric is a biopharmaceutical company focused on developing innovative cancer therapies targeting epigenetic mechanisms. The company's primary product, CCS1477, is a first-in-class p300/CBP inhibitor designed to treat specific cancers, including prostate cancer, blood cancers such as multiple myeloma and acute myeloid leukemia (AML), and other targeted tumors. CellCentric operates in the highly specialized oncology market, serving patients with challenging cancer types that have limited treatment options.
The business model revolves around the research, development, and clinical trials of novel cancer therapies, with a strong emphasis on scientific rigor and clinical validation. Revenue is primarily generated through partnerships, licensing agreements, and potential future sales of approved therapies.
CellCentric's approach leverages cutting-edge research in epigenetics, which studies changes in gene expression that do not involve alterations to the underlying DNA sequence. This focus allows the company to develop targeted treatments that can potentially improve outcomes for patients with difficult-to-treat cancers.
Keywords: biopharmaceutical, cancer therapies, epigenetics, p300/CBP inhibitor, prostate cancer, blood cancers, multiple myeloma, AML, clinical trials, oncology.